Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)

F. Foley (1) , I. -K. Penner , Gilles Edan (2, 3) , M. S. Freedman , X. Montalban , H. -P. Hartung , B. Hemmer , E. J. Fox , F. Barkhof (4) , S. Schippling (5) , R. Koelbach , D. Pleimes , C. Pohl , R. Sandbrink , G. Suarez , E. -M. Wicklein , Ludwig Kappos (6)

1 Yeshiva University
2 Service de Neurologie [Rennes] = Neurology [Rennes]
3 CIC - Centre d'Investigation Clinique [Rennes]
4 VU - Vrije Universiteit Amsterdam [Amsterdam]
5 Hôpital universitaire de Zurich
6 University Hospital Basel [Basel]

no abstract

Domaines: Sciences du Vivant [q-bio]

F. Foley, I. -K. Penner, Gilles Edan, M. S. Freedman, X. Montalban, et al.. Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11). Multiple Sclerosis Journal, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.249--251. ⟨hal-01259395⟩